The constitutive activity of ghrelin receptors is decreased by co-expression with vasoactive prostanoid receptors when over-expressed in human embryonic kidney 293 cells

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 11, 2008, Pages 2627-2637

  Chow, Kevin B S ^a   Leung, Po Ki ^a   Cheng, Christopher H K ^a   Cheung, Wing Tai ^a   Wise, Helen ^a  

^a Chinese University of Hong Kong   (Hong Kong)

Author keywords

Ghrelin receptors; Hetero oligomerization; Prostacyclin receptors; Prostaglandin E2 receptors; Thromboxane A2 receptors

Indexed keywords

GROWTH HORMONE SECRETAGOGUE RECEPTOR; PHOSPHOLIPASE C; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR SUBTYPE EP3 I; PROSTANOID RECEPTOR; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL STRAIN HEK293; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INFLAMMATION; OLIGOMERIZATION; PROTEIN FAMILY; PROTEIN LOCALIZATION; VASCULARIZATION;

CELL LINE; ENZYME ACTIVATION; HUMANS; PROTEIN ISOFORMS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GHRELIN; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; RECOMBINANT FUSION PROTEINS; TYPE C PHOSPHOLIPASES;

EID: 48349110896     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.05.008     Document Type: Article

References (56)

1. 1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nature Medicine 7 (2001) 1003-1009
2. Angers S., Salahpour A., and Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annual Reviews of Pharmacology and Toxicology 42 (2002) 409-435
3. Benkirane M., Jin D.Y., Chun R.F., Koup R.A., and Jeang K.T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by cc5Δ32. Journal of Biological Chemistry 272 (1997) 30603-30606
4. Bikkavilli R.K., Tsang S.Y., Tang W.M., Sun J.X., Ngai S.M., Lee S.S.T., et al. Identification and characterization of surrogate peptide ligand for orphan G protein-coupled receptor mas using phage-displayed peptide library. Biochemical Pharmacology 71 (2006) 319-337
5. Bilson H.A., Mitchell D.L., and Ashby B. Human prostaglandin EP3 receptor isoforms show different agonist-induced internalization patterns. FEBS Letters 572 (2004) 271-275
6. Cao J.M., Ong H., and Chen C. Effects of ghrelin and synthetic GH secretagogues on the cardiovascular system. Trends in Endocrinology and Metabolism 17 (2006) 13-18
7. Chow K.B.S., Wong Y.H., and Wise H. Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics. British Journal of Pharmacology 134 (2001) 1375-1384
8. Chu K.M., Chow K.B.S., Leung P.K., Lau P.N., Chan C.B., Cheng C.H.K., et al. Over-expression of the truncated ghrelin receptor polypeptide attenuates the constitutive activation of phosphatidylinositol-specific phospholipase C by ghrelin receptors but has no effect on ghrelin-stimulated extracellular signal-regulated kinase 1/2 activity. International Journal of Biochemistry and Cell Biology 39 (2007) 752-764
9. Cipollone F., and Fazia M.L. COX-2 and atherosclerosis. Journal of Cardiovascular Pharmacology 47 (2006) S26-S36
10. 1A-adrenoceptors. Biochemical Journal 343 (1999) 231-239
11. Ding W.Q., Cheng Z.J., McElhiney J., Kuntz S.M., and Miller L.J. Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. Cancer Research 62 (2002) 5223-5229
12. Dixit V.D., Schaffer E.M., Pyle R.S., Collins G.D., Sakthivel S.K., Palaniappan R., et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. Journal of Clinical Investigation 114 (2004) 57-66
13. Elmhurst J.L., Xie Z., O'Dowd B.F., and George S.R. The splice variant D3nf reduces ligand binding to the D3 dopamine receptor: evidence for heterooligomerization. Molecular Brain Research 80 (2000) 63-74
14. Galés C., Rebois R.V., Hogue M., Trieu P., Breit A., Hébert T.E., et al. Real-time monitoring of receptor and G-protein interactions in living cells. Nature Methods 2 (2005) 177-184
15. Gómez-Hernández A., Martín-Ventura J.L., Sánchez-Galán E., Vidal C., Ortego M., Blanco-Colio L.M., et al. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-κB. Atherosclerosis 187 (2006) 139-149
16. Grosse R., Schöneberg T., Schultz G., and Gudermann T. Inhibition of gonandotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Molecular Endocrinology 11 (1997) 1305-1318
17. 1B-adrenergic receptors. Journal of Biological Chemistry 279 (2004) 15541-15549
18. Hébert T.E., Galés C., and Rebois R.V. Detecting and imaging protein-protein interactions during G protein-mediated signal transduction in vivo and in situ by using fluorescence-based techniques. Cell Biochemistry and Biophysics 45 (2006) 85-109
19. 2-receptors in human platelets. Journal of Pharmacology and Experimental Therapeutics 245 (1988) 786-792
20. 2 vasopressin receptors are retained in different compartments of the early secretory pathway. Traffic 5 (2004) 993-1005
21. 60 to Leu mutation. Journal of Clinical Investigation 97 (1996) 949-956
22. Holliday N.D., Holst B., Rodionova E.A., Schwartz T.W., and Cox H.M. Importance of constitutive activity and arrestin independent mechanisms for intracellular trafficking of the ghrelin receptor. Molecular Endocrinology 21 (2007) 3100-3112
23. Holst B., Cygankiewicz A., Jensen T.H., Ankersen M., and Schwartz T.W. High constitutive signaling of the ghrelin receptor-identification of a potent inverse agonist. Molecular Endocrinology 17 (2003) 2201-2210
24. Holst B., Holliday N.D., Bach A., Elling C.E., Cox H.M., and Schwartz T.W. Common structural basis for constitutive activity of the ghrelin receptor family. Journal of Biological Chemistry 279 (2004) 53806-53817
25. Holst B., and Schwartz T.W. Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends in Pharmacological Sciences 25 (2004) 113-117
26. Karpa K.D., Lin R., Kabbani N., and Levenson R. The dopamine D3 receptor interacts with itself and the truncated D3 splice variant D3nf: D3-D3nf interaction causes mislocalization of D3 receptors. Molecular Pharmacology 58 (2000) 677-683
27. 1 receptor antagonist losartan. British Journal of Pharmacology 134 (2001) 1385-1392
28. 2 signalling in humans: a 'tail' of two receptors. Biochemical Society Transactions 29 (2001) 641-654
29. Kleinz M.J., Maguire J.J., Skepper J.N., and Davenport A.P. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovascular Research 69 (2006) 227-235
30. Leung P.K., Chow K.B.S., Lau P.N., Chu K.M., Chan C.B., Cheng C.H.K., et al. The truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the ghrelin receptor. Cellular Signalling 19 (2007) 1011-1022
31. Maggio R., Novi F., Scarselli M., and Corsini G.U. The impact of G-protein-coupled receptor hetero-oligomerization on function and pharmacology. FEBS Journal 272 (2005) 2939-2946
32. Maguire J.J., and Davenport A.P. Regulation of vascular reactivity by established and emerging GPCRs. Trends in Pharmacological Sciences 26 (2005) 448-454
33. B receptors-the first 7TM heterodimers. Trends in Pharmacological Sciences 20 (1999) 396-399
34. 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. Journal of Biological Chemistry 277 (2002) 44925-44931
35. 2 receptor (TP) α and β isoforms. Biochimica Biophysica Acta 1425 (1998) 543-559
36. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Molecular Pharmacology 66 (2004) 1-7
37. Muccioli G., Ghè C., Ghigo M.C., Papotti M., Arvat E., Boghen M.F., et al. Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland. Journal of Endocrinology 157 (1998) 99-106
38. 2 receptor. Advances in Experimental Medicine and Biology 433 (1997) 47-50
39. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structure, properties, and functions. Physiological Reviews 79 (1999) 1193-1226
40. 1 subtype. Journal of Biological Chemistry 271 (1997) 31255-31261
41. Okumura H., Nagaya N., Enomoto M., Nakagawa E., Oya H., and Kangawa K. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. Journal of Cardiovascular Pharmacology 39 (2002) 779-783
42. Pantel J., Legendre M., Cabrol S., Hilal L., Hajaji Y., Morisset S., et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. Journal of Clinical Investigation 116 (2006) 760-768
43. Paul B.Z.S., Ashby B., and Sheth S.B. Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells. British Journal of Haematology 102 (1998) 1204-1211
44. Ramsay D., Kellett E., McVey M., Rees S., and Milligan G. Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochemical Journal 365 (2002) 429-440
45. Rebois R.V., Robitaille M., Galés C., Dupré D.J., Baragli A., Trieu P., et al. Heterotrimeric G proteins form stable complexes with adenylyl cyclase and Kir3.1 channels in living cells. Journal of Cell Science 119 (2006) 2807-2818
46. Salahpour A., Angers S., and Bouvier M. Functional significance of oligomerization of G-protein-coupled receptors. Trends in Endocrinology and Metabolism 11 (2000) 163-168
47. 2. European Journal of Biochemistry 228 (1995) 23-30
48. Trettel F., Bartolomeo S., Lauro C., Catalano M., Ciotti M.T., and Limatola C. Ligand-independent CXCR2 dimerization. Journal of Biological Chemistry 278 (2003) 40980-40988
49. Waseem T., Duxbury M., Ito H., Ashley S.W., and Robinson M.K. Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery 143 (2008) 334-342
50. Wiley K.E., and Davenport A.P. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. British Journal of Pharmacology 136 (2002) 1146-1152
51. 4 receptor antagonist. British Journal of Pharmacology 148 (2006) 326-339
52. Wilson S., Wilkinson G., and Milligan G. The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities. Journal of Biological Chemistry 280 (2005) 28663-28674
53. Wilson S.J., Dowling J.K., Zhao L., Carnish E., and Smyth E.M. Regulation of thromboxane receptor trafficking through the prostacyclin receptor in vascular smooth muscle cells. Role of receptor heterodimerization. Arteriosclerosis Thrombosis and Vascular Biology 27 (2007) 290-296
54. Wilson S.J., Roche A.M., Kostetskaia E., and Smyth E.M. Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. Journal of Biological Chemistry 279 (2004) 53036-53047
55. Wu R., Zhou M., Cui X., Simms H.H., and Wang P. Upregulation of cardiovascular ghrelin receptor occurs in the hyperdynamic phase of sepsis. American Journal of Physiology 287 (2004) H1296-H1302
56. Zhu X., and Wess J. Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function. Biochemistry 37 (1998) 15773-15784